Relevant bibliographies by topics / Achromobacter spp

Contents

  1. Journal articles
  2. Book chapters
  3. Conference papers

Academic literature on the topic 'Achromobacter spp'

Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Achromobacter spp.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Achromobacter spp"

1

Chernukha, M. Yu, L. R. Avetisyan, E. V. Rusakova, V. D. Sherman, E. K. Zhekayte, E. G. Tselikina, and I. R. Fatkhullina. "Epidemiological role of chronic lung infection caused by Achromobacter in patients with cystic fibrosis." Voprosy praktičeskoj pediatrii 17, no. 3 (2022): 20–25. http://dx.doi.org/10.20953/1817-7646-2022-3-20-25.

Full text
Abstract:
Achromobacter is a genus of nonfermenting gram-negative bacteria that have particular clinical importance for patients with cystic fibrosis. Objective. To analyze epidemiological role of chronic lung infection caused by Achromobacter in patients with cystic fibrosis in Russia. Patients and methods. We examined 142 Achromobacter spp. isolates from sputum samples and throat swabs collected from 89 children and 53 adults. We used bacteriological and molecular methods (PCR, WGS) for identification and typing. Results. Our results demonstrated that newly identified chronic lung infection caused by Achromobacter spp. can be both nosocomial and community-acquired. Pathogens with different genotypes (ST36, ST261, ST184) are transmissive. Types ST36 and ST261 are found in several continents. Since 33.3% of patients infected with Achromobacter spp. were also found to have A. ruhlandii ST36, it can be defined as an epidemic clone. Our findings suggest high clinical and epidemiological importance of Achromobacter spp. Key words: Achromobacter spp., cystic fibrosis, a chronic lung infection
APA, Harvard, Vancouver, ISO, and other styles
2

Avetisyan, L. R., M. Yu Chernukha, V. G. Zhukhovitsky, E. V. Rusakova, E. M. Burmistrov, O. S. Medvedeva, N. B. Polyakov, et al. "Microbiological monitoring of chronic lung infection caused by Achromobacter spp. in patients with cystic fibrosis." Voprosy praktičeskoj pediatrii 17, no. 3 (2022): 26–32. http://dx.doi.org/10.20953/1817-7646-2022-3-26-32.

Full text
Abstract:
Objective. To provide a rationale for microbiological monitoring of chronic lung infection caused by Achromobacter spp. in patients with cystic fibrosis (CF) to develop an adequate preventive and therapeutic strategy. Materials and methods. This study included 142 Achromobacter strains isolated from 55 children and 35 adults with CF during their follow-up. In this study, classical microbiological (culture) and modern molecular genetic methods (polymerase chain reaction (PCR), multilocus sequence typing (MLST) and whole-genome sequencing (WGS)), and MALDI-TOF-MS were used. Results. Among the examined patients with chronic lung infection caused by bacteria from the genus Achromobacter, monoinfection was detected in 5.8% of patients. In other cases, associations of Achromobacter spp. with other bacterial species were observed. A. ruhlandii (76%) and A. xylosoxidans (7.2%) were the most frequently isolated species. It was shown that the microbiota in CF patients with chronic lung infection caused by Achromobacter spp. is characterized by variability and is related to long-term circulation of both one genotype with different subpopulation phenotypes and circulation of 2 or more genotypes or species of Achromobacter spp., which has clinical and epidemiological significance. Conclusion. Successful prevention and treatment of Achromobacter spp.-associated infections in CF patients require continuous microbiological monitoring of chronic infection, including that of phenotypic and genotypic properties of Achromobacter spp. strains isolated from patients. Key words: chronic lung infection, Achromobacter sp., microbiological monitoring, genotypic and phenotypic heterogeneity, sensitivity to antibiotics
APA, Harvard, Vancouver, ISO, and other styles
3

Bocharova, Y. A., T. A. Saviniova, A. V. Chaplin, Artem V. Lyamin, O. V. Kondratenko, S. V. Polikarpova, S. V. Zhilina, et al. "Genomic properties in Achromobacter spp. strains from cystic fibrosis patients in Russia." Clinical Microbiology and Antimicrobial Chemotherapy 23, no. 3 (2021): 220–25. http://dx.doi.org/10.36488/cmac.2021.3.220-225.

Full text
Abstract:
Objective. To determine species, sequence-types, antimicrobial resistance and virulence genes in Achromobacter spp. isolates obtained from cystic fibrosis (CF) patients in Russia. Materials and Methods. Samples (sputum, nasopharyngeal swab) from 168 CF patients from 48 regions were studied. Whole-genome sequencing (WGS) was performed on MGISEQ-2000 platform. SPAdes software, Galaxy, ResFinder, Integrall, PubMLST were used for analysis of WGS data. Results. A total of 18 strains of Achromobacter spp. were isolated from 16 of 168 CF patients.Achromobacter xylosoxidans was the most prevalent and detected in 13⁄18 cases (72%). Studied Achromobacter spp. isolates belonged to 14 sequence types, including 8 new sequence types. An adaptive resistance gene carriage was a rare phenomenon (1⁄18 isolates). Conclusions. The Achromobacter spp. colonization rate of respiratory system in CF patients in Russia corresponds to the data reported in other countries. A. xylosoxidans isolates were the most prevalent (72%). Achromobacter spp. isolates from CF patients in Russia and show a high clonal diversity.
APA, Harvard, Vancouver, ISO, and other styles
4

Crone, Cornelia Geisler, Omid Rezahosseini, Hans Henrik Lawaetz Schultz, Tavs Qvist, Helle Krogh Johansen, Susanne Dam Nielsen, and Michael Perch. "Achromobacter spp. in a Cohort of Non-Selected Pre- and Post-Lung Transplant Recipients." Pathogens 11, no. 2 (January 28, 2022): 181. http://dx.doi.org/10.3390/pathogens11020181.

Full text
Abstract:
Achromobacter is an opportunistic pathogen that mainly causes chronic lung infections in cystic fibrosis (CF) patients and is associated with increased mortality. Little is known about Achromobacter spp. in the lung transplant recipient (LTXr) population. We aimed at describing rates of Achromobacter spp. infection in LTXr prior to, in relation to, and after transplantation, as well as all-cause mortality proportion in infected and uninfected LTXr. We included 288 adult LTXr who underwent lung transplantation (LTX) between 1 January 2010 and 31 December 2019 in Denmark. Bronchoalveolar lavage was performed at regular intervals starting two weeks after transplantation. Positive cultures of Achromobacter spp. were identified in nationwide microbiology registries, and infections were categorized as persistent or transient, according to the proportion of positive cultures. A total of 11 of the 288 LTXr had transient (n = 7) or persistent (n = 4) Achromobacter spp. infection after LTX; CF was the underlying disease in 9 out of 11 LTXr. Three out of the four patients, with persistent infection after LTX, also had persistent infection before LTX. The cumulative incidence of the first episode of infection one year after LTX was 3.8% (95% CI: 1.6–6.0). The incidence rates of transient and persistent infection in the first year after LTX were 27 (12–53) and 15 (5–37) per 1000 person-years of follow-up, respectively. The all-cause mortality proportion one year after LTX was 27% in the Achromobacter spp. infected patients and 12% in the uninfected patients (p = 0.114). Achromobacter spp. mainly affected LTXr with CF as the underlying disease and was rare in non-CF LTXr. Larger studies are needed to assess long-term outcomes of Achromobacter spp. in LTXr.
APA, Harvard, Vancouver, ISO, and other styles
5

Tripathi, Nishant, Niki Koirala, Hirotaka Kato, Tushi Singh, Kishore Karri, and Kshitij Thakur. "First Documented Case of Percutaneous Endoscopic Gastrostomy (PEG) Tube-Associated Bacterial Peritonitis due to Achromobacter Species with Literature Review." Case Reports in Gastrointestinal Medicine 2020 (January 16, 2020): 1–11. http://dx.doi.org/10.1155/2020/4397930.

Full text
Abstract:
Introduction. Achromobacter species (spp.) peritonitis has seldom been identified in medical literature. Scarce cases of Achromobacter peritonitis described previously have been correlated with peritoneal dialysis and more sparingly with spontaneous bacterial peritonitis. Achromobacter exhibits intrinsic and acquired resistance, especially in chronic infections, to most antibiotics. This article conducts a literature review of all previously reported Achromobacter spp. peritonitis and describes the first reported case of Achromobacter peritonitis as a complication of percutaneous endoscopic gastrostomy (PEG) tube placement. Discussion. Achromobacter peritonitis as a complication of PEG-tube placement has not been previously reported. In our patients’ case, the recently placed PEG-tube with ascitic fluid leakage was identified as the most plausible infection source. Although a rare bacterial peritonitis pathogen, Achromobacter may be associated with wide antimicrobial resistance and unfavorable outcomes. Conclusion. No current guidelines provide significant guidance on treatment of PEG-tube peritonitis regardless of microbial etiology. Infectious Disease Society of America identifies various broad-spectrum antibiotics targeting nosocomial intra-abdominal coverage; some of these antimicrobial selections (such as cefepime and metronidazole combination) may yet be inadequate for widely resistant Achromobacter spp. Recognizably, the common antibiotics utilized for spontaneous bacterial peritonitis, i.e., third generation cephalosporins and fluoroquinolones, to which Achromobacter is resistant and variably susceptible, respectively, would be extensively insufficient. Piperacillin/tazobactam (P/T) and carbapenem were identified to provide the most reliable coverage in vitro; clinically, 5 out of the 8 patients who received either P/T or a carbapenem, or both, eventually experienced clinical improvement.
APA, Harvard, Vancouver, ISO, and other styles
6

AMOUREUX, L., J. BADOR, T. VERRIER, H. MJAHED, C. DE CURRAIZE, and C. NEUWIRTH. "Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non-respiratory samples." Epidemiology and Infection 144, no. 16 (August 18, 2016): 3527–30. http://dx.doi.org/10.1017/s0950268816001564.

Full text
Abstract:
SUMMARYAchromobacter spp. are emerging opportunistic Gram-negative rods responsible for diverse nosocomial or community-acquired infections. We describe, for the first time, the distribution of Achromobacter spp., defined by nrdA gene sequencing, and their antimicrobial susceptibility in a variety of non-respiratory samples recovered from hospitalized patients from 2010 to 2015. Of the 63 isolates studied, A. xylosoxidans was the most prevalent (41 isolates), and with the exception of A. insuavis (four isolates), the remaining 10 species identified were represented by one or two isolates only. All isolates were uniformly susceptible to piperacillin and piperacillin-tazobactam and 97% to meropenem, but 76% showed resistance to ciprofloxacin. This study confirms the diversity of Achromobacter spp. in non-cystic fibrosis (CF) isolates and the predominance of A. xylosoxidans, as previously reported for CF sputum isolates. There was no apparent link between the clinical site of infection and the species of Achromobacter.
APA, Harvard, Vancouver, ISO, and other styles
7

Parra-Vera, Henry Junior, Galo Guillermo Farfán-Cano, and Dayci Colombia Buele-Chica. "Panorama microbiológico de Achromobacter spp. Como potencial agente infeccioso - Microbiological overview of Achromobacter spp. As a potential infectious agent." Investigatio 20 (March 31, 2023): 74–85. http://dx.doi.org/10.31095/investigatio.2023.20.6.

Full text
Abstract:
Introducción: Achromobacter es un género que viene ganando importancia como patógenos raros y oportunistas de tipo nosocomial en el último decenio, sus reportes de caso vienen aumentando, de ahí la importancia de revisar el estado acerca de estos microorganismos. Métodos: se incluyeron publicaciones que analizaran aspectos microbiológicos del género y su relación con infecciones en humanos, a los cuales se accedió por medio de una búsqueda sistemática de información en base de datos de Pubmed efectuada el 15 de septiembre de 2022; el sesgo de selección se aminoro con criterios de exclusión (estudios en animales, artículos que exploren otros géneros y no Achromobacter y Achromobacter sin relación a infecciones en seres humanos). Resultados: de la búsqueda se obtuvo 92 artículos de los cuales 46 cumplieron los criterios de inclusión. Conclusiones: es un género ubicuo, patógeno oportunista en humanos, causante de infecciones nosocomiales, con resistencia intrínseca a un amplio espectro de antimicrobianos.
APA, Harvard, Vancouver, ISO, and other styles
8

Ronin, Eve, Christian Derancourt, André Cabié, and Karine Marion-Sanchez. "Achromobacter spp. Surgical Site Infections: A Systematic Review of Case Reports and Case Series." Microorganisms 9, no. 12 (November 30, 2021): 2471. http://dx.doi.org/10.3390/microorganisms9122471.

Full text
Abstract:
Achromobacter species are isolated from rare but severe healthcare-associated infections, including surgical site infections. They are considered to preferentially infect immunocompromised patients but so far with limited evidence. We conducted a systematic review on Achromobacter spp. surgical site infections (SSIs) to determine if such infections were indeed more commonly associated with immunocompromised patients. The secondary objective was to describe the characteristics of infected patients. Eligible articles had to be published before 30 September 2020 and to report Achromobacter spp. SSIs across all surgical specialties excluding ophthalmology. Analyses were performed on individual data without meta-analysis. Cases were divided into 2 subgroups: one group which had either prosthesis or implant and the other group which did not. A first selection led to a review of 94 articles, of which 37 were analyzed. All were case reports or case series and corresponded to 49 infected patients. Most of the patients were under 65 years of age and had undergone a heart or digestive surgery followed by deep infection with no co-infecting pathogens. Nine out of the 49 cases were immunocompromised, with similar distribution between the two subgroups (16.6% and 20%, respectively). This review suggests that Achromobacter spp. SSIs do not preferentially target immunocompromised patients.
APA, Harvard, Vancouver, ISO, and other styles
9

Kendi Celebi, Zeynep, Serkan Akturk, Gulden Celik, Selma Yalcin, Kenan Ates, and Oktay Karatan. "CAPD-Associated Peritonitis with Achromobacter SPP.: Case Report." Turkish Nephrology Dialysis Transplantation 24, no. 2 (May 18, 2015): 210–11. http://dx.doi.org/10.5262/tndt.2015.1002.12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sandri, Angela, Janus Anders Juul Haagensen, Laura Veschetti, Helle Krogh Johansen, Søren Molin, Giovanni Malerba, Caterina Signoretto, Marzia Boaretti, and Maria M. Lleo. "Adaptive Interactions of Achromobacter spp. with Pseudomonas aeruginosa in Cystic Fibrosis Chronic Lung Co-Infection." Pathogens 10, no. 8 (August 3, 2021): 978. http://dx.doi.org/10.3390/pathogens10080978.

Full text
Abstract:
In the lungs of patients with cystic fibrosis (CF), the main pathogen Pseudomonas aeruginosa is often co-isolated with other microbes, likely engaging in inter-species interactions. In the case of chronic co-infections, this cohabitation can last for a long time and evolve over time, potentially contributing to the clinical outcome. Interactions involving the emerging pathogens Achromobacter spp. have only rarely been studied, reporting inhibition of P. aeruginosa biofilm formation. To evaluate the possible evolution of such interplay, we assessed the ability of Achromobacter spp. isolates to affect the biofilm formation of co-isolated P. aeruginosa strains during long-term chronic co-infections. We observed both competition and cohabitation. An Achromobacter sp. isolate secreted exoproducts interfering with the adhesion ability of a co-isolated P. aeruginosa strain and affected its biofilm formation. Conversely, a clonal Achromobacter sp. strain later isolated from the same patient, as well as two longitudinal strains from another patient, did not show similar competitive behavior against its P. aeruginosa co-isolates. Genetic variants supporting the higher virulence of the competitive Achromobacter sp. isolate were found in its genome. Our results confirm that both inter-species competition and cohabitation are represented during chronic co-infections in CF airways, and evolution of these interplays can happen even at the late stages of chronic infection.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Achromobacter spp"

1

Kumar, Sampath, and Kamaljit Singh. "Miscellaneous gram-negative organisms." In Schlossberg's Clinical Infectious Disease, edited by Cheston B. Cunha, 1045–52. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190888367.003.0160.

Full text
Abstract:
Most gram-negative infections are caused by organisms in the Enterobacteriaceae or the Pseudomonas genus, and a few are caused by a heterogeneous group of miscellaneous gram-negative organisms. Acinetobacter is a member of the family Moraxellaceae, which includes A. calcoaceticus, A. lwoffii, and A. baumannii as the most commonly reported in the clinical literature. Achromobacter spp. are widely distributed in soil and water, and they may be part of the normal flora of the lower gastrointestinal tract. The chapter describes the genus Alcaligenes, which consist of gram-negative rods or cocci that are oxidase positive and obligate aerobes. A. faecalis as the most commonly isolated species in the clinical laboratory.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Achromobacter spp"

1

Syed, ZA, and W. Flight. "P112 Incidence and clinical outcomes of pulmonary infection with achromobacter spp." In British Thoracic Society Winter Meeting 2017, QEII Centre Broad Sanctuary Westminster London SW1P 3EE, 6 to 8 December 2017, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2017. http://dx.doi.org/10.1136/thoraxjnl-2017-210983.254.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Achromobacter spp' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography